Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Up 4.4% – Here’s What Happened

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) was up 4.4% during trading on Monday . The stock traded as high as $5.39 and last traded at $5.22. Approximately 1,545,002 shares were traded during trading, a decline of 4% from the average daily volume of 1,602,808 shares. The stock had previously closed at $5.00.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CATX. Truist Financial started coverage on Perspective Therapeutics in a report on Monday, November 24th. They issued a “buy” rating and a $12.00 target price for the company. HC Wainwright raised their price objective on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. UBS Group reiterated a “buy” rating and issued a $7.00 price objective (down from $18.00) on shares of Perspective Therapeutics in a research note on Friday, November 21st. Piper Sandler began coverage on shares of Perspective Therapeutics in a research report on Thursday, February 19th. They set an “overweight” rating and a $16.00 target price on the stock. Finally, Wedbush reissued an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research note on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, Perspective Therapeutics has an average rating of “Buy” and a consensus target price of $12.38.

Perspective Therapeutics Stock Performance

The firm has a fifty day simple moving average of $4.22 and a 200-day simple moving average of $3.41. The company has a quick ratio of 8.66, a current ratio of 8.66 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.51) EPS for the quarter. Perspective Therapeutics had a negative net margin of 9,841.86% and a negative return on equity of 40.03%. The firm had revenue of $0.04 million for the quarter. Equities research analysts anticipate that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current year.

Institutional Trading of Perspective Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. AXQ Capital LP raised its holdings in Perspective Therapeutics by 24.2% during the fourth quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after buying an additional 2,481 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Perspective Therapeutics by 6.1% during the fourth quarter. Deutsche Bank AG now owns 54,245 shares of the company’s stock valued at $149,000 after buying an additional 3,119 shares during the last quarter. Vontobel Holding Ltd. increased its position in shares of Perspective Therapeutics by 25.0% during the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $69,000 after acquiring an additional 5,000 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Perspective Therapeutics by 184.1% during the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after acquiring an additional 5,475 shares in the last quarter. Finally, Taylor & Morgan Wealth Management LLC raised its holdings in shares of Perspective Therapeutics by 6.6% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 97,000 shares of the company’s stock worth $267,000 after acquiring an additional 6,000 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.